NCT07076212View on ClinicalTrials.gov

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Metastatic Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma
Interventions
DRUG

Liposomal Irinotecan

50 mg/m2 will be administered on Day 1 of a 2-week cycle

DRUG

Oxaliplatin

60 mg/m2 will be administered on Day 1 of a 2-week cycle

DRUG

5-Fluorouracil

5-fluorouracil (2400 mg/m2 over 46 hours) will begin administration on Day 1 of a 2-week cycle

DRUG

Leucovorin

400 mg/m2 will be administered on Day 1 of a 2-week cycle

DRUG

Gemcitabine (mg/m²)

1000 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle

DRUG

Nab-paclitaxel

125 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle

DRUG

Cisplatin

25 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle

Trial Locations (1)

29425

Medical University of South Carolina Hollings Cancer Center, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER